# A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

> **NCT06745323** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 252 (actual)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** Tarlatamab

## Key facts

- **NCT ID:** NCT06745323
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-26
- **Primary completion:** 2029-02-09
- **Final completion:** 2029-02-09
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06745323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06745323, "A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06745323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*